Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry Combined with Magnetic Beads for Detecting Serum Protein Biomarkers in Parkinson’s Disease
Background: Biomarkers for neurodegenerative diseases are essential to facilitate disease diagnosis. Application of proteomics has greatly hastened the search for novel biomarkers. In this study, new potential biomarkers were discovered, and a diagnostic pattern was established for idiopathic Parkin...
Saved in:
Published in | European neurology Vol. 65; no. 2; pp. 105 - 111 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Basel, Switzerland
S. Karger AG
01.02.2011
|
Subjects | |
Online Access | Get full text |
ISSN | 0014-3022 1421-9913 1421-9913 |
DOI | 10.1159/000323427 |
Cover
Abstract | Background: Biomarkers for neurodegenerative diseases are essential to facilitate disease diagnosis. Application of proteomics has greatly hastened the search for novel biomarkers. In this study, new potential biomarkers were discovered, and a diagnostic pattern was established for idiopathic Parkinson’s disease (PD) by using proteomic technology. Methods: Serum proteins from PD patients and controls were captured by magnetic bead-based weak cation exchange. The molecular weight of the proteins in bead-binding fraction was detected by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS). Biomarker Wizard 3.1 and Biomarker Patterns Software were used for data analysis and constructing a model of biomarkers. A blinded testing set was used to validate the model. Results: A total of 17 discriminating m/z peaks related to PD were identified. The model based on the 5 biomarkers generated an excellent separation between PD and healthy controls with 98.36% for the sensitivity and 83.05% for the specificity. Blind test data demonstrated the model could recognize patients with PD with a sensitivity of 85.0% and a specificity of 70.0%. Conclusions: The preliminary data suggested a potential application of MALDI-TOF-MS combined with magnetic beads. The model comprising 5 promising biomarkers can differentiate individuals with PD and the healthy subjects precisely. |
---|---|
AbstractList | Background: Biomarkers for neurodegenerative diseases are essential to facilitate disease diagnosis. Application of proteomics has greatly hastened the search for novel biomarkers. In this study, new potential biomarkers were discovered, and a diagnostic pattern was established for idiopathic Parkinson’s disease (PD) by using proteomic technology. Methods: Serum proteins from PD patients and controls were captured by magnetic bead-based weak cation exchange. The molecular weight of the proteins in bead-binding fraction was detected by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS). Biomarker Wizard 3.1 and Biomarker Patterns Software were used for data analysis and constructing a model of biomarkers. A blinded testing set was used to validate the model. Results: A total of 17 discriminating m/z peaks related to PD were identified. The model based on the 5 biomarkers generated an excellent separation between PD and healthy controls with 98.36% for the sensitivity and 83.05% for the specificity. Blind test data demonstrated the model could recognize patients with PD with a sensitivity of 85.0% and a specificity of 70.0%. Conclusions: The preliminary data suggested a potential application of MALDI-TOF-MS combined with magnetic beads. The model comprising 5 promising biomarkers can differentiate individuals with PD and the healthy subjects precisely. Biomarkers for neurodegenerative diseases are essential to facilitate disease diagnosis. Application of proteomics has greatly hastened the search for novel biomarkers. In this study, new potential biomarkers were discovered, and a diagnostic pattern was established for idiopathic Parkinson's disease (PD) by using proteomic technology.BACKGROUNDBiomarkers for neurodegenerative diseases are essential to facilitate disease diagnosis. Application of proteomics has greatly hastened the search for novel biomarkers. In this study, new potential biomarkers were discovered, and a diagnostic pattern was established for idiopathic Parkinson's disease (PD) by using proteomic technology.Serum proteins from PD patients and controls were captured by magnetic bead-based weak cation exchange. The molecular weight of the proteins in bead-binding fraction was detected by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS). Biomarker Wizard 3.1 and Biomarker Patterns Software were used for data analysis and constructing a model of biomarkers. A blinded testing set was used to validate the model.METHODSSerum proteins from PD patients and controls were captured by magnetic bead-based weak cation exchange. The molecular weight of the proteins in bead-binding fraction was detected by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS). Biomarker Wizard 3.1 and Biomarker Patterns Software were used for data analysis and constructing a model of biomarkers. A blinded testing set was used to validate the model.A total of 17 discriminating m/z peaks related to PD were identified. The model based on the 5 biomarkers generated an excellent separation between PD and healthy controls with 98.36% for the sensitivity and 83.05% for the specificity. Blind test data demonstrated the model could recognize patients with PD with a sensitivity of 85.0% and a specificity of 70.0%.RESULTSA total of 17 discriminating m/z peaks related to PD were identified. The model based on the 5 biomarkers generated an excellent separation between PD and healthy controls with 98.36% for the sensitivity and 83.05% for the specificity. Blind test data demonstrated the model could recognize patients with PD with a sensitivity of 85.0% and a specificity of 70.0%.The preliminary data suggested a potential application of MALDI-TOF-MS combined with magnetic beads. The model comprising 5 promising biomarkers can differentiate individuals with PD and the healthy subjects precisely.CONCLUSIONSThe preliminary data suggested a potential application of MALDI-TOF-MS combined with magnetic beads. The model comprising 5 promising biomarkers can differentiate individuals with PD and the healthy subjects precisely. Background: Biomarkers for neurodegenerative diseases are essential to facilitate disease diagnosis. Application of proteomics has greatly hastened the search for novel biomarkers. In this study, new potential biomarkers were discovered, and a diagnostic pattern was established for idiopathic Parkinson's disease (PD) by using proteomic technology. Methods: Serum proteins from PD patients and controls were captured by magnetic bead-based weak cation exchange. The molecular weight of the proteins in bead-binding fraction was detected by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS). Biomarker Wizard 3.1 and Biomarker Patterns Software were used for data analysis and constructing a model of biomarkers. A blinded testing set was used to validate the model. Results: A total of 17 discriminating m/z peaks related to PD were identified. The model based on the 5 biomarkers generated an excellent separation between PD and healthy controls with 98.36% for the sensitivity and 83.05% for the specificity. Blind test data demonstrated the model could recognize patients with PD with a sensitivity of 85.0% and a specificity of 70.0%. Conclusions: The preliminary data suggested a potential application of MALDI-TOF-MS combined with magnetic beads. The model comprising 5 promising biomarkers can differentiate individuals with PD and the healthy subjects precisely. Copyright [copy 2011 S. Karger AG, Basel Background: Biomarkers for neurodegenerative diseases are essential to facilitate disease diagnosis. Application of proteomics has greatly hastened the search for novel biomarkers. In this study, new potential biomarkers were discovered, and a diagnostic pattern was established for idiopathic Parkinson's disease (PD) by using proteomic technology. Methods: Serum proteins from PD patients and controls were captured by magnetic bead-based weak cation exchange. The molecular weight of the proteins in bead-binding fraction was detected by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS). Biomarker Wizard 3.1 and Biomarker Patterns Software were used for data analysis and constructing a model of biomarkers. A blinded testing set was used to validate the model. Results: A total of 17 discriminating m/z peaks related to PD were identified. The model based on the 5 biomarkers generated an excellent separation between PD and healthy controls with 98.36% for the sensitivity and 83.05% for the specificity. Blind test data demonstrated the model could recognize patients with PD with a sensitivity of 85.0% and a specificity of 70.0%. Conclusions: The preliminary data suggested a potential application of MALDI-TOF-MS combined with magnetic beads. The model comprising 5 promising biomarkers can differentiate individuals with PD and the healthy subjects precisely. Copyright © 2011 S. Karger AG, Basel [PUBLICATION ABSTRACT] Biomarkers for neurodegenerative diseases are essential to facilitate disease diagnosis. Application of proteomics has greatly hastened the search for novel biomarkers. In this study, new potential biomarkers were discovered, and a diagnostic pattern was established for idiopathic Parkinson's disease (PD) by using proteomic technology. Serum proteins from PD patients and controls were captured by magnetic bead-based weak cation exchange. The molecular weight of the proteins in bead-binding fraction was detected by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS). Biomarker Wizard 3.1 and Biomarker Patterns Software were used for data analysis and constructing a model of biomarkers. A blinded testing set was used to validate the model. A total of 17 discriminating m/z peaks related to PD were identified. The model based on the 5 biomarkers generated an excellent separation between PD and healthy controls with 98.36% for the sensitivity and 83.05% for the specificity. Blind test data demonstrated the model could recognize patients with PD with a sensitivity of 85.0% and a specificity of 70.0%. The preliminary data suggested a potential application of MALDI-TOF-MS combined with magnetic beads. The model comprising 5 promising biomarkers can differentiate individuals with PD and the healthy subjects precisely. |
Author | Wang, Jian Li, Yao-Hua Chan, Piu Zheng, Xiao-Li Zhang, Yan-Li He, Xin Li, Xin Yu, Shun |
Author_xml | – sequence: 1 givenname: Yao-Hua surname: Li fullname: Li, Yao-Hua email: liyaohua1962@yahoo.com.cn – sequence: 2 givenname: Jian surname: Wang fullname: Wang, Jian – sequence: 3 givenname: Xiao-Li surname: Zheng fullname: Zheng, Xiao-Li – sequence: 4 givenname: Yan-Li surname: Zhang fullname: Zhang, Yan-Li – sequence: 5 givenname: Xin surname: Li fullname: Li, Xin email: liyaohua1962@yahoo.com.cn – sequence: 6 givenname: Shun surname: Yu fullname: Yu, Shun – sequence: 7 givenname: Xin surname: He fullname: He, Xin – sequence: 8 givenname: Piu surname: Chan fullname: Chan, Piu email: liyaohua1962@yahoo.com.cn |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/21273779$$D View this record in MEDLINE/PubMed |
BookMark | eNqFks9u1DAQxi1URLeFA3eELC4Vh7D-E8fJsd1SqLQVlVrOkZNMtm439uJxBO2J1-AReC2eBC-77KFC4jQzmt98suebA7LnvANCXnL2jnNVTRljUshc6CdkwnPBs6rico9MGON5JpkQ--QA8TaVqtLlM7IvuNBS62pCfl6YGOy37BjRYoSOzg1CoKeAPqyi9W567p19MOuUXtsBMt9nZ0u7uIn0wiDSqxW0MfgBYrinMz801iWVrzbepP7CQbQtPQHTIe39Wjcm3LoFvYIwDvQy-AjW0RPrBxPuICBN1WVKrUPvfn3_gfTUIqRHPSdPe7NEeLGNh-Tz2fvr2cds_unD-ex4nrWyyGOmgBXKVKoxTSmUMn3B8hxaqUthyrwqDWdKs64Qus_bTpZFztqOdVxB33UNGHlIjja6q-C_jICxHiy2sFwaB37Euiy0llKK4v-kksmISupEvnlE3voxuPSNBOVCca5Vgl5vobEZoKtXwaad3Nd_zUrA2w3QBo8YoN8hnNXrQ6h3h5DY6SO2tfGPizEYu_znxKvNxJ0JCwg77W37NyMUv4c |
CODEN | EUNEAP |
CitedBy_id | crossref_primary_10_1016_j_bbapap_2015_01_016 crossref_primary_10_1007_s12035_013_8590_8 crossref_primary_10_1371_journal_pone_0079733 crossref_primary_10_1002_jcla_21694 crossref_primary_10_1007_s12010_013_0238_7 crossref_primary_10_1016_j_pneurobio_2011_09_002 crossref_primary_10_1007_s13758_012_0066_2 crossref_primary_10_3109_15622975_2011_598712 crossref_primary_10_1007_s12640_019_00080_4 crossref_primary_10_1002_mds_26635 crossref_primary_10_1586_14737175_2016_1135056 crossref_primary_10_1002_mds_25065 crossref_primary_10_1042_BSR20150023 crossref_primary_10_1016_j_neuint_2013_06_005 |
Cites_doi | 10.1093%2Fbrain%2F114.5.2283 10.1038%2F35086067 10.1097%2FMLG.0b013e31814cf389 10.1016%2FS0304-3940%2802%2901259-4 10.1074%2Fmcp.R200007-MCP200 10.1200%2FJCO.2005.03.164 10.1093%2Fhmg%2Fddm159 10.1038%2Fnm1113 10.1016%2Fj.schres.2006.02.016 10.1002%2Fmds.10305 10.1021%2Fpr0703526 10.1136%2Fjnnp.55.3.181 10.1373%2Fclinchem.2004.032458 10.1038%2Fnrc2011 10.1002%2Fana.410240415 10.1146%2Fannurev.neuro.28.061604.135718 |
ContentType | Journal Article |
Copyright | 2011 S. Karger AG, Basel Copyright © 2011 S. Karger AG, Basel. Copyright (c) 2011 S. Karger AG, Basel |
Copyright_xml | – notice: 2011 S. Karger AG, Basel – notice: Copyright © 2011 S. Karger AG, Basel. – notice: Copyright (c) 2011 S. Karger AG, Basel |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7TK 7X7 7XB 88E 88G 88I 8AF 8AO 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. M0S M1P M2M M2P PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS PSYQQ Q9U S0X 7X8 |
DOI | 10.1159/000323427 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Neurosciences Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Psychology Database (Alumni) Science Database (Alumni Edition) STEM Database ProQuest Pharma Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni) Medical Database Psychology Database (ProQuest) Science Database ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest One Psychology ProQuest Central Basic SIRS Editorial MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Psychology ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials SIRS Editorial ProQuest Health & Medical Complete (Alumni) ProQuest AP Science ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Science Journals (Alumni Edition) ProQuest Central Basic ProQuest Science Journals ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Psychology Journals (Alumni) Neurosciences Abstracts ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest Psychology Journals ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | CrossRef MEDLINE - Academic Neurosciences Abstracts ProQuest One Psychology MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central Database Suite (ProQuest) url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1421-9913 |
EndPage | 111 |
ExternalDocumentID | 2279246501 21273779 10_1159_000323427 323427 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- .55 .GJ 0R~ 0~5 0~B 29G 30W 325 34G 36B 39C 3O. 3V. 4.4 53G 5GY 5RE 7X7 88E 88I 8AF 8AO 8FI 8FJ 8UI AAYIC ABIVO ABJNI ABPAZ ABUWG ACGFO ACGFS ACGOD ACPRK ACPSR ADAGL ADBBV ADFRT ADGES AENEX AEYAO AFJJK AFKRA AFOSN AHMBA AI. ALDHI ALIPV ALMA_UNASSIGNED_HOLDINGS AZPMC AZQEC BENPR BPHCQ BVXVI CAG CCPQU COF CS3 CYUIP DU5 DWQXO E0A EBS EJD EMB EMOBN F5P FB. FYUFA GNUQQ HCIFZ HMCUK HZ~ IY7 KUZGX M1P M2M M2P N9A O1H O9- P2P PQQKQ PROAC PSQYO PSYQQ RIG RKO RXVBD S0X SV3 UJ6 UKHRP VH1 X7M ZGI ZXP AAYXX ABBTS ABWCG ACQXL AFSIO AHFRZ CITATION PHGZM PHGZT CGR CUY CVF ECM EIF NPM PJZUB PPXIY 7TK 7XB 8FK K9. PKEHL PQEST PQUKI PRINS Q9U 7X8 PUEGO |
ID | FETCH-LOGICAL-c364t-5e065a95bab8255af6044ec3782a8498a10570d627f4cd38640cd0d15efddbea3 |
IEDL.DBID | 7X7 |
ISSN | 0014-3022 1421-9913 |
IngestDate | Thu Sep 04 16:15:25 EDT 2025 Fri Sep 05 03:16:29 EDT 2025 Sat Aug 23 13:31:27 EDT 2025 Mon Jul 21 05:29:42 EDT 2025 Thu Apr 24 23:12:00 EDT 2025 Tue Jul 01 05:10:22 EDT 2025 Thu Aug 29 12:04:14 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Keywords | Parkinsonߣs disease MALDI-TOF-MS Weak cationic exchange magnetic beads Proteomics Biomarkers diagnosis |
Language | English |
License | Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. https://www.karger.com/Services/SiteLicenses Copyright © 2011 S. Karger AG, Basel. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c364t-5e065a95bab8255af6044ec3782a8498a10570d627f4cd38640cd0d15efddbea3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Article-2 ObjectType-Feature-1 |
PMID | 21273779 |
PQID | 854251175 |
PQPubID | 41501 |
PageCount | 7 |
ParticipantIDs | proquest_miscellaneous_867733326 crossref_primary_10_1159_000323427 proquest_miscellaneous_853991937 karger_primary_323427 pubmed_primary_21273779 proquest_journals_854251175 crossref_citationtrail_10_1159_000323427 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2011-02-00 |
PublicationDateYYYYMMDD | 2011-02-01 |
PublicationDate_xml | – month: 02 year: 2011 text: 2011-02-00 |
PublicationDecade | 2010 |
PublicationPlace | Basel, Switzerland |
PublicationPlace_xml | – name: Basel, Switzerland – name: Switzerland – name: Basel |
PublicationTitle | European neurology |
PublicationTitleAlternate | Eur Neurol |
PublicationYear | 2011 |
Publisher | S. Karger AG |
Publisher_xml | – name: S. Karger AG |
References | Thomas B, Beal MF: Parkinson’s disease. Hum Mol Genet 2007;16:183–194.10.1093%2Fhmg%2Fddm159 Mian S, Ugurel S, Parkinson E, Schlenzka I, Dryden I, Lancashire L, Ball G, Creaser C, Rees R, Schadendorf D: Serum proteomic fingerprinting discriminates between clinical stages and predicts disease progression in melanoma patients. J Clin Oncol 2005;23:5088–5093.1605195510.1200%2FJCO.2005.03.164 Abe T, Isobe C, Murata T, Sato C, Tohgi H: Alteration of 8-hydroxyguanosine concentrations in the cerebrospinal fluid and serum from patients with Parkinson’s disease. Neurosci Lett 2003;336:105–108.1249905110.1016%2FS0304-3940%2802%2901259-4 Lin XL, Yang SY, Du J, Tian YX, Bu LN, Huo SF, Wang FP, Nan YD: Detection of lung adenocarcinoma using magnetic beads-based matrix-assisted laser desorption/ionization time-of-flight mass spectrometry serum protein profiling. Chin Med J 2010;123:34–39.20137572 Freed GL, Cazares LH, Fichandler CE, Fuller TW, Sawyer CA, Stack BC Jr, Schraff S, Semmes OJ, Wadsworth JT, Drake RR: Differential capture of serum proteins for expression profiling and biomarker discovery in pre- and posttreatment head and neck cancer samples. Laryngoscope 2008;118:61–68.1804349710.1097%2FMLG.0b013e31814cf389 Hughes AJ, Daniel SE, Kilford L, Lees AJ: Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181–184.156447610.1136%2Fjnnp.55.3.181 McNaught KS, Olanow CW, Halliwell B, Isacson O, Jenner P: Failure of the ubiquitin-proteasome system in Parkinson’s disease. Nat Rev Neurosci 2001;2:589–594.1148400210.1038%2F35086067 Breiman L, Friedman JH, Olshen RA, Stone CJ: Classification and Regression Trees. Belmont, Wadsworth, 1984. Twelves D, Perkins KS, Counsell C: Systematic review of incidence studies of Parkinson’s disease. Mov Disord 2003;18:19–31.1251829710.1002%2Fmds.10305 Li J, Zhang Z, Rosenzweig J, Wang YY, Chan DW: Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 2002;48:1296–1304.12142387 Pahwa R, Lyons KE: Early diagnosis of Parkinson’s disease: recommendations from diagnostic clinical guidelines. Am J Manag Care 2010;16:94–99. Petricoin EF, Belluco C, Araujo RP, Liotta LA: The blood peptidome: a higher dimension of information content for cancer biomarker discovery. Nat Rev Cancer 2006;6:961–967.1709350410.1038%2Fnrc2011 Anderson NL, Anderson NG: The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 2002;1:845–867.1248846110.1074%2Fmcp.R200007-MCP200 Dotzlaw H, Schulz M, Eggert M, Neeck G: A pattern of protein expression in peripheral blood mononuclear cells distinguishes rheumatoid arthritis patients from healthy individuals. Biochim Biophys Acta 2004;1696:121–129.14726212 Forman MS, Trojanowski JQ, Lee VM: Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs. Nat Med 2004;10:1055–1063.1545970910.1038%2Fnm1113 Kang X, Xu Y, Wu X, Liang Y, Wang C, Guo J, Wang Y, Chen M, Wu D, Wang Y, Bi S, Qiu Y, Lu P, Cheng J, Xiao B, Hu L, Gao X, Liu J, Wang Y, Song Y, Zhang L, Suo F, Chen T, Huang Z, Zhao Y, Lu H, Pan C, Tang H: Proteomic fingerprints for potential application to early diagnosis of severe acute respiratory syndrome. Clin Chem 2005;51:56–64.1555047910.1373%2Fclinchem.2004.032458 McGeer PL, Itagaki S, Akiyama H, McGeer EG: Rate of cell death in parkinsonism indicates active neuropathological process. Ann Neurol 1988;24:574–576.323995710.1002%2Fana.410240415 Gatlin-Bunai CL, Cazares LH, Cooke WE, Semmes OJ, Malyarenko DI: Optimization of MALDI-TOF-MS detection for enhanced sensitivity of affinity-captured proteins spanning a 100-kDa mass range. J Proteome Res 2007;6:4517–4524.1791887410.1021%2Fpr0703526 Zhang X, Leung SM, Morris CR, Shigenaga MK: Evaluation of a novel, integrated approach using functionalized magnetic beads, bench-top MALDI-TOF-MS with prestructured sample supports, and pattern recognition software for profiling potential biomarkers in human plasma. J Biomol Tech 2004;15:167–175.15331582 Moore DJ, West AB, Dawson VL, Dawson TM: Molecular pathophysiology of Parkinson’s disease. Annu Rev Neurosci 2005;28:57–87.1602259010.1146%2Fannurev.neuro.28.061604.135718 Fearnley JM, Lees AJ: Ageing and Parkinson’s disease: substantia nigra regional selectivity. Brain 1991;114:2283–2301.193324510.1093%2Fbrain%2F114.5.2283 Mei J, Kolbin D, Kao HT, Porton B: Protein expression profiling of postmortem brain in schizophrenia. Schizophr Res 2006;84:204–213.1662453210.1016%2Fj.schres.2006.02.016 McDonald WH, Yates JR: Shotgun proteomics and biomarker discovery. Dis Markers 2002;18:99–105.12364816 ref13 ref12 ref15 ref14 ref11 ref10 ref2 ref1 ref16 ref8 ref7 ref9 ref4 ref3 ref6 ref5 |
References_xml | – reference: Pahwa R, Lyons KE: Early diagnosis of Parkinson’s disease: recommendations from diagnostic clinical guidelines. Am J Manag Care 2010;16:94–99. – reference: Mian S, Ugurel S, Parkinson E, Schlenzka I, Dryden I, Lancashire L, Ball G, Creaser C, Rees R, Schadendorf D: Serum proteomic fingerprinting discriminates between clinical stages and predicts disease progression in melanoma patients. J Clin Oncol 2005;23:5088–5093.1605195510.1200%2FJCO.2005.03.164 – reference: Forman MS, Trojanowski JQ, Lee VM: Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs. Nat Med 2004;10:1055–1063.1545970910.1038%2Fnm1113 – reference: Gatlin-Bunai CL, Cazares LH, Cooke WE, Semmes OJ, Malyarenko DI: Optimization of MALDI-TOF-MS detection for enhanced sensitivity of affinity-captured proteins spanning a 100-kDa mass range. J Proteome Res 2007;6:4517–4524.1791887410.1021%2Fpr0703526 – reference: Dotzlaw H, Schulz M, Eggert M, Neeck G: A pattern of protein expression in peripheral blood mononuclear cells distinguishes rheumatoid arthritis patients from healthy individuals. Biochim Biophys Acta 2004;1696:121–129.14726212 – reference: Moore DJ, West AB, Dawson VL, Dawson TM: Molecular pathophysiology of Parkinson’s disease. Annu Rev Neurosci 2005;28:57–87.1602259010.1146%2Fannurev.neuro.28.061604.135718 – reference: Freed GL, Cazares LH, Fichandler CE, Fuller TW, Sawyer CA, Stack BC Jr, Schraff S, Semmes OJ, Wadsworth JT, Drake RR: Differential capture of serum proteins for expression profiling and biomarker discovery in pre- and posttreatment head and neck cancer samples. Laryngoscope 2008;118:61–68.1804349710.1097%2FMLG.0b013e31814cf389 – reference: Li J, Zhang Z, Rosenzweig J, Wang YY, Chan DW: Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 2002;48:1296–1304.12142387 – reference: Fearnley JM, Lees AJ: Ageing and Parkinson’s disease: substantia nigra regional selectivity. Brain 1991;114:2283–2301.193324510.1093%2Fbrain%2F114.5.2283 – reference: Abe T, Isobe C, Murata T, Sato C, Tohgi H: Alteration of 8-hydroxyguanosine concentrations in the cerebrospinal fluid and serum from patients with Parkinson’s disease. Neurosci Lett 2003;336:105–108.1249905110.1016%2FS0304-3940%2802%2901259-4 – reference: Zhang X, Leung SM, Morris CR, Shigenaga MK: Evaluation of a novel, integrated approach using functionalized magnetic beads, bench-top MALDI-TOF-MS with prestructured sample supports, and pattern recognition software for profiling potential biomarkers in human plasma. J Biomol Tech 2004;15:167–175.15331582 – reference: Lin XL, Yang SY, Du J, Tian YX, Bu LN, Huo SF, Wang FP, Nan YD: Detection of lung adenocarcinoma using magnetic beads-based matrix-assisted laser desorption/ionization time-of-flight mass spectrometry serum protein profiling. Chin Med J 2010;123:34–39.20137572 – reference: McGeer PL, Itagaki S, Akiyama H, McGeer EG: Rate of cell death in parkinsonism indicates active neuropathological process. Ann Neurol 1988;24:574–576.323995710.1002%2Fana.410240415 – reference: Anderson NL, Anderson NG: The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 2002;1:845–867.1248846110.1074%2Fmcp.R200007-MCP200 – reference: McDonald WH, Yates JR: Shotgun proteomics and biomarker discovery. Dis Markers 2002;18:99–105.12364816 – reference: Twelves D, Perkins KS, Counsell C: Systematic review of incidence studies of Parkinson’s disease. Mov Disord 2003;18:19–31.1251829710.1002%2Fmds.10305 – reference: Breiman L, Friedman JH, Olshen RA, Stone CJ: Classification and Regression Trees. Belmont, Wadsworth, 1984. – reference: Petricoin EF, Belluco C, Araujo RP, Liotta LA: The blood peptidome: a higher dimension of information content for cancer biomarker discovery. Nat Rev Cancer 2006;6:961–967.1709350410.1038%2Fnrc2011 – reference: Thomas B, Beal MF: Parkinson’s disease. Hum Mol Genet 2007;16:183–194.10.1093%2Fhmg%2Fddm159 – reference: Hughes AJ, Daniel SE, Kilford L, Lees AJ: Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181–184.156447610.1136%2Fjnnp.55.3.181 – reference: Kang X, Xu Y, Wu X, Liang Y, Wang C, Guo J, Wang Y, Chen M, Wu D, Wang Y, Bi S, Qiu Y, Lu P, Cheng J, Xiao B, Hu L, Gao X, Liu J, Wang Y, Song Y, Zhang L, Suo F, Chen T, Huang Z, Zhao Y, Lu H, Pan C, Tang H: Proteomic fingerprints for potential application to early diagnosis of severe acute respiratory syndrome. Clin Chem 2005;51:56–64.1555047910.1373%2Fclinchem.2004.032458 – reference: McNaught KS, Olanow CW, Halliwell B, Isacson O, Jenner P: Failure of the ubiquitin-proteasome system in Parkinson’s disease. Nat Rev Neurosci 2001;2:589–594.1148400210.1038%2F35086067 – reference: Mei J, Kolbin D, Kao HT, Porton B: Protein expression profiling of postmortem brain in schizophrenia. Schizophr Res 2006;84:204–213.1662453210.1016%2Fj.schres.2006.02.016 – ident: ref2 doi: 10.1093%2Fbrain%2F114.5.2283 – ident: ref5 doi: 10.1038%2F35086067 – ident: ref16 doi: 10.1097%2FMLG.0b013e31814cf389 – ident: ref13 doi: 10.1016%2FS0304-3940%2802%2901259-4 – ident: ref6 doi: 10.1074%2Fmcp.R200007-MCP200 – ident: ref8 doi: 10.1200%2FJCO.2005.03.164 – ident: ref1 doi: 10.1093%2Fhmg%2Fddm159 – ident: ref10 doi: 10.1038%2Fnm1113 – ident: ref9 doi: 10.1016%2Fj.schres.2006.02.016 – ident: ref12 doi: 10.1002%2Fmds.10305 – ident: ref14 doi: 10.1021%2Fpr0703526 – ident: ref3 doi: 10.1136%2Fjnnp.55.3.181 – ident: ref7 doi: 10.1373%2Fclinchem.2004.032458 – ident: ref15 doi: 10.1038%2Fnrc2011 – ident: ref4 doi: 10.1002%2Fana.410240415 – ident: ref11 doi: 10.1146%2Fannurev.neuro.28.061604.135718 |
SSID | ssj0015978 |
Score | 2.0187845 |
Snippet | Background: Biomarkers for neurodegenerative diseases are essential to facilitate disease diagnosis. Application of proteomics has greatly hastened the search... Biomarkers for neurodegenerative diseases are essential to facilitate disease diagnosis. Application of proteomics has greatly hastened the search for novel... |
SourceID | proquest pubmed crossref karger |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 105 |
SubjectTerms | Adult Aged Biomarkers - blood Blood Proteins - analysis Female Humans Immunomagnetic Separation - methods Male Middle Aged Original Paper Parkinson Disease - blood Parkinson Disease - diagnosis Proteomics - methods Sensitivity and Specificity Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization - methods Young Adult |
Title | Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry Combined with Magnetic Beads for Detecting Serum Protein Biomarkers in Parkinson’s Disease |
URI | https://karger.com/doi/10.1159/000323427 https://www.ncbi.nlm.nih.gov/pubmed/21273779 https://www.proquest.com/docview/854251175 https://www.proquest.com/docview/853991937 https://www.proquest.com/docview/867733326 |
Volume | 65 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1ba9RQEB60FfFFvFRdq-Uggr4cmm7ObZ_E1S5V3FLEwr6Fc9tSbJM2yUL9Rf5NZ5KT4IP2cZMhgZ3JzDdnZr4BeOu0iUF5Wu4SDRchGO6cM9wHb5VR0maehpOXx-roVHxdyVXqzWlSW-XgEztHHSpPZ-T7RgpCw1p-uLrmtDSKiqtpg8Zd2O6Yy9Cc9WrMtzBQD46YDv-n00QshNdpfiGf5oJ2yfwVju79pO7r-v9gsws6i0fwMKFF9rFX72O4E8sncH-Z6uFP4feSGPZvOP7JpK7AvmFQqhkmk1Xd-YL9L9Uwaclo2oNXa764oIScLRE2M1o_3xJjQVv_YugbME_Gp9DhLN4_K2nCkc3RDBqG4BafSyUHDHYMXczmkp0QycN5yebn1SW1-dQNw180SN3NlL1r2Oe-_rMDp4vDH5-OeFq9wH2uRMtlRGhiZ9JZhymktGuVCRF9jnjCGjEzltYDZ0FN9Vr4kBslMh-ycCDjOgQXbf4MtsqqjC-AGdpubf2BIiYaZdEfEI2dV85q45S2E3g_aKDwiZec1mNcFF1-ImfFqKwJvBlFr3oyjn8J7fRqHEWG67uDVov0nTbFaFUTYONd_MCoamLLWG1IBDEcwlx9i4jSOs8RCE_geW8u47uJQJ84HV_e-vZdeNCfVVObzCvYautNfI1gp3V7nUnvwfb88Pjk-x86-wA_ |
linkProvider | ProQuest |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VLQIuiEehS3lYCAQXq2niON4DQiztapduVhVqpd5Sx_aiqm1Skqygv4gT_5GZvMQBeusxycg5zHjmG4_nG4A3aaSclYaGuzjFhbWKp2mquLFGSyVD7RlqTo4XcnokvhyHx2vwu-uFoWuVnU-sHbXNDZ2Rb6tQEBqOwo-X3zkNjaLiajdBo7GKfXf1AzO28sNsF9X71vcne4efp7wdKsBNIEXFQ4dBV4_CVKeYHIV6KT0hnAkwUmolRkrT4FvPSj9aCmMDJYVnrGd3Qre0NnU6wHVvwbqghtYBrI_3Fgdf-7IFovPW9VO5wfdbKiN8Tx0TgR8Iml7zVwC8fUb3vYv_w9s6zE0ewP0Wn7JPjUE9hDWXPYI7cVuBfwy_YuL0_8lRrWQgls0xDBYM09e8qL3P9izvejsZ9ZfwfMkn53QEwGIE6owG3lfEkVAVVwy9EWbmuAodB-P3bxn1VLIxGl7JEE7julTkwPDK0KmtLtgB0UqcZmx8ml_QxaKiZPhErdt1F9u7ku02FacNOLoRvTyBQZZnbhOYonna2uxI4r6RGj0QEecZmepIpTLSQ3jfaSAxLRM6DeQ4T-qMKBwlvbKG8LoXvWzoP_4ltNGosRfp3m91Wk1az1AmvR0PgfVfcUtTnUZnLl-RCKJGBNbRNSIyioIAofcQnjbm0v-bKPuJRfLZtX9_BXenh_E8mc8W-1twrzkpp0s6z2FQFSv3AqFWlb5sDZzByU3vqT_Y3j0Q |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKQVUviEeBpTwsBIKLtWns2N4DQpRl1aXdqhJU2lvwK6hqN1mSXUF_Eb-Bf8dMXuIAvfUYZ2QfZjzzjedFyEurdPDS4XCXoJnwXjNrrWbOOyO1TEzksDh5diwPTsWneTLfIL-7WhhMq-x0Yq2ofeHwjXyoE4FoWCXDrM2KOBlP3i2_MxwghYHWbppGIyGH4fIHeG_V2-kYWP0qjicfv3w4YO2AAea4FCuWBDDAZpRYY8FRSkwmIyGC42A1jRYjbXAIbuRlrDLhPNdSRM5Hfi8Jmfc2GA773iA3FQdQBVdJzXtfD0BCZwQw8BDHbVMjWMfaCR5zgXNs_jKFt84x87v8P9CtDd7kDrndIlX6vhGtu2Qj5PfI1qyNxd8nv2bY3f8nAwajqHh6BAaxpODIFmWth4bToqvypFhpwoqMTS7wMYDOALLTz8t6As8irMpLCnoJfHTYBR-G4f-3HKsr6T6IYEUBWMO-GO4AQ0tBva0X9AQbTJzldP-sWGCKUVlR-MIi7rqe7XVFx03saYecXgtXHpDNvMjDI0I1TtY2bk9iFxxpQBdhCz0nrVHaSmUG5E3HgdS1PdFxNMdFWvtGySjtmTUgL3rSZdMI5F9EOw0be5JufbfjatrqiCrtJXpAaP8XLjdGbEweijWSAH4EiK2uIJFKcQ4gfEAeNuLSn43N-7Gf5OMrT39OtuAmpUfT48Ndst08mWO2zhOyuSrX4SlgrpV9Vks3JV-v-zr9Af5DP9c |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Matrix-assisted+laser+desorption%2Fionization+time-of-flight+mass+spectrometry+combined+with+magnetic+beads+for+detecting+serum+protein+biomarkers+in+parkinson%27s+disease&rft.jtitle=European+neurology&rft.au=Li%2C+Yao-Hua&rft.au=Wang%2C+Jian&rft.au=Zheng%2C+Xiao-Li&rft.au=Zhang%2C+Yan-Li&rft.date=2011-02-01&rft.issn=1421-9913&rft.eissn=1421-9913&rft.volume=65&rft.issue=2&rft.spage=105&rft_id=info:doi/10.1159%2F000323427&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0014-3022&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0014-3022&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0014-3022&client=summon |